

AMENDMENTS

In the Claims:

Claims 1-10. (Cancelled)

Claim 11. (Currently Amended) A mutant *ras* peptide consisting of:
Xaa₁ Leu Xaa₂ Val Val Gly Ala Xaa₃ Gly Val Gly Lys Ser (SEQ ID NO:14);
wherein Xaa₁ is the amino acid lysine or tyrosine;
wherein Xaa₂ is an amino acid;
wherein Xaa₃ is selected from the group consisting of aspartic acid,
valine, cysteine, alanine, arginine, and serine;
wherein when Xaa₂ is valine, Xaa₁ is tyrosine
and said peptide elicits a peptide-specific human CD8⁺ cytotoxic T
lymphocyte immune response ~~The mutant *ras* peptide of claim 10, wherein the~~
~~peptide consists of 13 amino acids.~~

Claim 12. (Currently Amended) A mutant *ras* peptide which is a fragment
of:
Xaa₁ Leu Xaa₂ Val Val Gly Ala Xaa₃ Gly Val Gly Lys Ser (SEQ ID NO:14);
wherein Xaa₁ is the amino acid lysine or tyrosine;
wherein Xaa₂ is an amino acid;
wherein Xaa₃ is selected from the group consisting of aspartic acid,
valine, cysteine, alanine, arginine, and serine;
wherein when Xaa₂ is valine, Xaa₁ is tyrosine
and said peptide elicits a peptide-specific human CD8⁺ cytotoxic T
lymphocyte immune response and wherein said fragment ~~The mutant *ras* peptide~~
~~of claim 10, wherein the peptide consists of 10 amino acids.~~

Claim 13. (Currently Amended) A mutant *ras* peptide consisting of between 13 and 8 amino acids, wherein said peptide is the following peptide or a fragment thereof:

Xaa₁ Leu Xaa₂ Val Val Gly Ala Xaa₃ Gly Val Gly Lys Ser (SEQ ID NO:14);
wherein Xaa₁ is the amino acid tyrosine;
wherein Xaa₂ is valine;
wherein Xaa₃ is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, and serine;
and said peptide elicits a peptide-specific human CD8⁺ cytotoxic T lymphocyte immune response
~~The mutant *ras* peptide of claim 10, wherein Xaa₁ is tyrosine.~~

Claim 14. (Currently Amended) A mutant *ras* peptide consisting of between 13 and 8 amino acids, wherein said peptide is the following peptide or a fragment thereof:

Xaa₁ Leu Xaa₂ Val Val Gly Ala Xaa₃ Gly Val Gly Lys Ser (SEQ ID NO:14);
wherein Xaa₁ is the amino acid lysine or tyrosine;
wherein Xaa₂ is selected from the group consisting of valine, tryptophan, leucine, tyrosine, and phenylalanine;
wherein Xaa₃ is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, and serine;
wherein when Xaa₂ is valine, Xaa₁ is tyrosine
and said peptide elicits a peptide-specific human CD8⁺ cytotoxic T lymphocyte immune response
~~The mutant *ras* peptide of claim 10, wherein Xaa₂ is selected from the group consisting of valine, tryptophan, leucine, tyrosine, and phenylalanine.~~

Claim 15. (Currently Amended) A mutant *ras* peptide consisting of between 13 and 8 amino acids, wherein said peptide is the following peptide or a fragment thereof:

Xaa₁ Leu Xaa₂ Val Val Gly Ala Xaa₃ Gly Val Gly Lys Ser (SEQ ID NO:14);
 wherein Xaa₁ is tyrosine;
 wherein Xaa₂ is an amino acid;
 wherein Xaa₃ aspartic acid;
 and said peptide elicits a peptide-specific human CD8⁺ cytotoxic T
lymphocyte immune response ~~The mutant *ras* peptide of claim 10, wherein Xaa₁~~
~~is tyrosine, and Xaa₃ is aspartic acid.~~

Claims 16-24. (Cancelled).

Claim 25. (Currently Amended) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide ~~of claim 10 or 72~~ consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide.

Claim 26. (Cancelled).

Claim 27. (Currently Amended) An immunogen for eliciting a mutant *ras* peptide-specific human CD8⁺ cytotoxic T lymphocyte immune response comprising a mutant *ras* peptide of claim ~~10 or 72~~, wherein the immunogen elicits a mutant *ras* peptide-specific human CD8⁺ cytotoxic T lymphocyte immune response.

Claims 28-31. (Cancelled).

Claim 32. (Currently Amended) A pharmaceutical composition comprising the mutant *ras* peptide of claim ~~10 or 72~~ and a pharmaceutically acceptable carrier.

Claim 33. (Previously presented) The pharmaceutical composition of claim 32, further comprising a biological response modifier.

Claim 34. (Previously presented) The pharmaceutical composition of claim 32, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claims 35-65. (Cancelled).

Claim 66. (Currently Amended) ~~The mutant *ras* peptide-carrier molecule conjugate of claim 25,~~ A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide and wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A, and poly-L-lysine.

Claim 67. (Currently Amended) ~~The mutant *ras* peptide-carrier molecule conjugate of claim 25,~~ A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide and wherein the carrier molecule is tetanus toxoid.

Claim 68. (Previously presented) The pharmaceutical composition of claim 33, wherein the biological response modifier is interleukin 2.

Claim 69. (Cancelled).

Claim 70. (Previously presented) The pharmaceutical composition of claim 32, further comprising interleukin 2, interleukin 6, interleukin 12, interferon, tumor necrosis factor, GM-CSF, β 2-microglobulin, or combinations thereof.

Claim 71. (Previously presented) The pharmaceutical composition of claim 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claim 72. (Previously presented) A mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:11).